Ropeg outperforms HU in PV patients of all ages
June 28, 2018|Hematology Times
Dr Kiladjian also pointed out that the number of adverse drug reactions (ADRs) was comparable between the treatment arms for younger patients, and there was a trend toward a lower number of ADRs in the ropeg arm for the patients age 60 and older.
| Safety results at a mean of 2.7 years of treatment (up to 3.6 years) | ||||
| Ropeg | HU | |||
| <60 (n=49) | ≥60 (n=46) | <60 (n=39) | ≥60 (n=37) | |
| Patients with any AE | 44 (89.8%) | 43 (93.5%) | 36 (92.3%) | 34 (91.1%) |
| Serious AE | 3 (6.1%) | 10 (21.7%) | 4 (10.3%) | 9 (24.3%) |
| ADR | 38 (77.6%) | 29 (63%) | 29 (74.4%) | 33 (89.2%) |
| Serious ADR | 0 | 0 | 0 | 4 (10.8%) |
| Grade 3+ AE | 10 (20.4%) | 16 (34.8%) | 10 (25.6%) | 14 (37.8%) |
| Recovered from AE | 43 (87.8%) | 40 (87%) | 35 (89.7%) | 34 (91.9%) |
The 4 serious ADRs in the HU patients age 60 and older were acute leukemia, anemia, leukopenia, and granulocytopenia.
